Talk Title: Mass spectrometry, proteomics and more
Mass spectrometry is one of the leading technologies to identify and globally quantify proteins in virtually every biological sample and environment. Due to its unparalleled sensitivity and accuracy, mass spectrometry is the method of choice for a plethora of applications ranging from biomarker discoveries to absolute quantification of low abundant peptide species.
In this presentation, I will give of an overview of mass spectrometry and how mass spectrometers can be used for the comprehensive analysis of proteins as well as their post-translational modifications. I will use current research projects of my lab to illustrate proteomic data as well as various mass spectrometric techniques and applications.
Dr Ralf Schittenhelm, Scientific Director, Proteomics Platform, Monash University
Ralf is the Director of the Monash Biomedical Proteomics Facility which provide mass spectrometric expertise to the broader community. Ralf’s research has utilised high-resolution mass spectrometry to study the onset and progression of a variety of clinically relevant diseases known as spondyloarthropathies, which are inflammatory rheumatic disorders. In earlier work, Ralf worked in the team that identified and validated novel components of the insulin receptor / target of rapamycin (InR/TOR) pathway using mass spectrometric approaches in combination with biochemical assays.